癌症：仍然是变应原免疫疗法的禁忌症吗？：特异性免疫疗法与癌症
Cancer: Still a contraindication for allergen immunotherapy?: Specific immunotherapy and cancer.
作者信息
El-Qutob David, Letrán Antonio, Matheu Victor, Fernandez-Caldas Enrique
机构信息
Allergy Unit, University Hospital of La Plana, Vila-real, Spain.
Allergy Unit, Hospital HLA Jerez Puerta del Sur, Jerez de la Frontera, Cádiz, Spain.
出版信息
World Allergy Organ J. 2021 Oct 15;14(10):100597. doi: 10.1016/j.waojou.2021.100597. eCollection 2021 Oct.
Allergen immunotherapy (AIT) is currently more than 100 years old. It is considered an evidence-based efficacious immune therapeutical treatment. It is at this time the only causative treatment for allergic respiratory and venom allergic diseases. Though clinical indications for AIT are well established, clinical contraindications to AIT differ among several guidelines. Regarding malignant neoplasia, traditionally, it has been considered as a relative or absolute contraindication with the concern that AIT might stimulate tumour growth even though pathogenic impact of AIT in cancer is not well understood. Furthermore, this contraindication is often based on observational case series, or case reports, with little real evidence-based data. Therefore, should cancer still be contemplated as an absolute contraindication for AIT?
变应原免疫疗法（AIT）目前已有100多年的历史。它被认为是一种基于证据的有效免疫治疗方法。目前，它是过敏性呼吸道疾病和毒液过敏疾病的唯一病因治疗方法。尽管AIT的临床适应症已得到充分确立，但不同指南中AIT的临床禁忌症存在差异。关于恶性肿瘤，传统上，它被视为相对或绝对禁忌症，原因是担心AIT可能刺激肿瘤生长，尽管AIT对癌症的致病影响尚未完全了解。此外，这种禁忌症往往基于观察性病例系列或病例报告，实际的循证数据很少。那么，癌症是否仍应被视为AIT的绝对禁忌症呢？
Zotero 插件